Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial
Authors:
- Saher HamedSHSaher Hamed
- Yehuda UllmannYUYehuda Ullmann
- Mark BelokopytovMBMark Belokopytov
- Aziz ShoufaniASAziz Shoufani
- Hoda KabhaHKHoda Kabha
- Suher MasriSMSuher Masri
- Muhamad SafadiMSMuhamad Safadi
- Zeev FeldbrinZFZeev Feldbrin
- Leonid KoganLKLeonid Kogan
- Danny KruchevskyDKDanny Kruchevsky
- Roger NajjarRNRoger Najjar
- Paul Y. LiuPLPaul Y. Liu
- 16 August 2021
- journal article
- research article
- Published by SAGE Publications in Rejuvenation Research
- Vol. 24 (4) , 251-261
Abstract
The diabetic foot ulcer (DFU) is a major disabling complication of diabetes mellitus. Growing evidence suggests that topical erythropoietin (EPO) can promote wound healing. The aim of this study is to clinically assess the efficacy of a proprietary topical EPO-containing hydrogel for treating DFUs. We conducted a randomized, controlled trial in 20 patients with DFUs. After a 14-day screening period, the DFUs of 20 eligible participants who fulfilled the inclusion criteria were randomly assigned (1:1) to either a 12-week of daily treatment with topical EPO and standard-of-care (SOC) or SOC treatment alone. The DFUs were assessed weekly until week 12. The primary outcome was 75% ulcer closure or higher. After 12 weeks of treatment, 75% ulcer closure was achieved in 6 of the 10 patients whose DFUs were treated with topical EPO and in one of the 8 patients whose DFUs were treated with SOC alone. The mean area of the DFUs that were treated with topical EPO and SOC was significantly smaller than those treated with SOC alone (1.2 ± 1.4 cm 2 vs. 4.2 ± 3.4 cm 2 ; p = 0.023). Re-epithelialization was faster in the topically EPO-treated DFUs than in the SOC-treated DFUs. There were no treatment-related adverse events. We conclude that topical EPO is a promising treatment for promoting the healing of DFUs. Clinical Trial Registration number: NCT02361931.Keywords
This publication has 31 references indexed in Scilit:
- Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitusWound Repair and Regeneration, 2013
- Mechanisms Involved in the Development and Healing of Diabetic Foot UlcerationDiabetes, 2012
- NorLeu3‐A(1–7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel‐group, double‐blind, placebo‐controlled phase 2 clinical trialWound Repair and Regeneration, 2012
- Fibronectin Potentiates Topical Erythropoietin-Induced Wound Repair in Diabetic MiceJournal of Investigative Dermatology, 2011
- Interactive Role of Trauma Cytokines and Erythropoietin and Their Therapeutic Potential for Acute and Chronic WoundsRejuvenation Research, 2011
- Topical Erythropoietin Promotes Wound Repair in Diabetic RatsJournal of Investigative Dermatology, 2010
- Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?Diabetes Research and Clinical Practice, 2009
- Erythropoietin inhibits cytokine production of neonatal and adult leukocytesActa Paediatrica, 2007
- Rate of Healing of Neuropathic Ulcers of the Foot in Diabetes and Its Relationship to Ulcer Duration and Ulcer AreaDiabetes Care, 2007
- The global burden of diabetic foot diseaseThe Lancet, 2005